Targeting PI3K inhibitor resistance in breast cancer with metabolic drugs

• Verfasst von: Gremke, Niklas [VerfasserIn]
• Verfasst von: Besong, Isabelle [VerfasserIn]
• Verfasst von: Stroh, Alina [VerfasserIn]
• Verfasst von: von Wichert, Luise [VerfasserIn]
• Verfasst von: Witt, Marie [VerfasserIn]
• Verfasst von: Elmshäuser, Sabrina [VerfasserIn]
• Verfasst von: Wanzel, Michael [VerfasserIn]
• Verfasst von: Fromm, Martin F. [VerfasserIn]
• Verfasst von: Taudte, R. Verena [VerfasserIn]
• Verfasst von: Schmatloch, Sabine [VerfasserIn]
• Verfasst von: Karn, Thomas [VerfasserIn]
• Verfasst von: Reinisch, Mattea [VerfasserIn]
• Verfasst von: Hirmas, Nader [VerfasserIn]
• Verfasst von: Loibl, Sibylle [VerfasserIn]
• Verfasst von: Wündisch, Thomas [VerfasserIn]
• Verfasst von: Litmeyer, Anne-Sophie [VerfasserIn]
• Verfasst von: Jank, Paul [VerfasserIn]
• Verfasst von: Denkert, Carsten [VerfasserIn]
• Verfasst von: Griewing, Sebastian [VerfasserIn]
• Verfasst von: Wagner, Uwe [VerfasserIn]
• Verfasst von: Stiewe, Thorsten [VerfasserIn]
• Titel: Targeting PI3K inhibitor resistance in breast cancer with metabolic drugs
• Verf.angabe: Niklas Gremke, Isabelle Besong, Alina Stroh, Luise von Wichert, Marie Witt, Sabrina Elmshäuser, Michael Wanzel, Martin F. Fromm, R. Verena Taudte, Sabine Schmatloch, Thomas Karn, Mattea Reinisch, Nader Hirmas, Sibylle Loibl, Thomas Wündisch, Anne-Sophie Litmeyer, Paul Jank, Carsten Denkert, Sebastian Griewing, Uwe Wagner and Thorsten Stiewe
• E-Jahr: 2025
• Jahr: 21 March 2025
• Umfang: 19 S.
• Illustrationen: Illustrationen
• Fussnoten: Gesehen am 16.07.2025
• Titel Quelle: Enthalten in: Signal transduction and targeted therapy
• Ort Quelle: London : Macmillan Publishers, part of Springer Nature, 2016
• Jahr Quelle: 2025
• Band/Heft Quelle: 10(2025), 1, Artikel-ID 92, Seite 1-19
• ISSN Quelle: 2059-3635
• DOI: doi:10.1038/s41392-025-02180-4
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Breast cancer
• Sach-SW: Drug development
• Sach-SW: Target identification
• K10plus-PPN: 1930679785

Abstract

Activating PIK3CA mutations, present in up to 40% of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (Her2−) breast cancer (BC) patients, can be effectively targeted with the alpha isoform-specific PI3K inhibitor Alpelisib. This treatment significantly improves outcomes for HR+, Her2−, and PIK3CA-mutated metastatic BC patients. However, acquired resistance, often due to aberrant activation of the mTOR complex 1 (mTORC1) pathway, remains a significant clinical challenge. Our study, using in vitro and orthotopic xenograft mouse models, demonstrates that constitutively active mTORC1 signaling renders PI3K inhibitor-resistant BC exquisitely sensitive to various drugs targeting cancer metabolism. Mechanistically, mTORC1 suppresses the induction of autophagy during metabolic perturbation, leading to energy stress, a critical depletion of aspartate, and ultimately cell death. Supporting this mechanism, BC cells with CRISPR/Cas9-engineered knockouts of canonical autophagy genes showed similar vulnerability to metabolically active drugs. In BC patients, high mTORC1 activity, indicated by 4E-BP1T37/46 phosphorylation, correlated with p62 accumulation, a sign of impaired autophagy. Together, these markers predicted poor overall survival in multiple BC subgroups. Our findings reveal that aberrant mTORC1 signaling, a common cause of PI3K inhibitor resistance in BC, creates a druggable metabolic vulnerability by suppressing autophagy. Additionally, the combination of 4E-BP1T37/46 phosphorylation and p62 accumulation serves as a biomarker for poor overall survival, suggesting their potential utility in identifying BC patients who may benefit from metabolic therapies.